Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Herpes Therapy Enters the Molecular Age.

Fife KH.

J Infect Dis. 2018 Oct 20;218(11):1689-1690. doi: 10.1093/infdis/jiy374. No abstract available.

PMID:
30020482
2.

Behavior and health beliefs as predictors of HIV testing among women: a prospective study of observed HIV testing.

Fan H, Fife KH, Cox D, Cox AD, Zimet GD.

AIDS Care. 2018 Aug;30(8):1062-1069. doi: 10.1080/09540121.2018.1442555. Epub 2018 Feb 22.

3.

Causal role for the subthalamic nucleus in interrupting behavior.

Fife KH, Gutierrez-Reed NA, Zell V, Bailly J, Lewis CM, Aron AR, Hnasko TS.

Elife. 2017 Jul 25;6. pii: e27689. doi: 10.7554/eLife.27689.

4.

Clinical Validation of a Test for the Diagnosis of Vaginitis.

Gaydos CA, Beqaj S, Schwebke JR, Lebed J, Smith B, Davis TE, Fife KH, Nyirjesy P, Spurrell T, Furgerson D, Coleman J, Paradis S, Cooper CK.

Obstet Gynecol. 2017 Jul;130(1):181-189. doi: 10.1097/AOG.0000000000002090.

5.

Ventral tegmental area glutamate neurons co-release GABA and promote positive reinforcement.

Yoo JH, Zell V, Gutierrez-Reed N, Wu J, Ressler R, Shenasa MA, Johnson AB, Fife KH, Faget L, Hnasko TS.

Nat Commun. 2016 Dec 15;7:13697. doi: 10.1038/ncomms13697.

6.

Human Papillomavirus DNA Detection in Older Women-Implications for Cancer Screening and Prevention.

Ermel AC, Fife KH.

J Infect Dis. 2016 Sep 1;214(5):657-8. doi: 10.1093/infdis/jiw075. Epub 2016 Mar 23. No abstract available.

7.

Transient Increase in Herpes Simplex Virus Type 2 (HSV-2)-Associated Genital Ulcers Following Initiation of Antiretroviral Therapy in HIV/HSV-2-Coinfected Individuals.

Fife KH, Mugwanya K, Thomas KK, Baeten JM, Celum C, Bukusi E, de Bruyn G, Mujugira A, Vwalika B, Wald A, Lingappa JR; Partners in Prevention HSV/HIV Transmission Study Team.

J Infect Dis. 2016 May 15;213(10):1573-8. doi: 10.1093/infdis/jiv765. Epub 2015 Dec 23.

8.

Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples.

Magaret AS, Mujugira A, Hughes JP, Lingappa J, Bukusi EA, DeBruyn G, Delany-Moretlwe S, Fife KH, Gray GE, Kapiga S, Karita E, Mugo NR, Rees H, Ronald A, Vwalika B, Were E, Celum C, Wald A; Partners in Prevention HSV/HIV Transmission Study Team.

Clin Infect Dis. 2016 Feb 15;62(4):456-61. doi: 10.1093/cid/civ908. Epub 2015 Nov 17.

9.

Frequency of false positive rapid HIV serologic tests in African men and women receiving PrEP for HIV prevention: implications for programmatic roll-out of biomedical interventions.

Ndase P, Celum C, Kidoguchi L, Ronald A, Fife KH, Bukusi E, Donnell D, Baeten JM; Partners PrEP Study Team.

PLoS One. 2015 Apr 17;10(4):e0123005. doi: 10.1371/journal.pone.0123005. eCollection 2015.

10.

The effects of HIV testing advocacy messages on test acceptance: a randomized clinical trial.

Kasting ML, Cox AD, Cox D, Fife KH, Katz BP, Zimet GD.

BMC Med. 2014 Nov 6;12:204. doi: 10.1186/s12916-014-0204-4.

11.

Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.

Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Coombs RW, Hendrix C, Marzinke MA, Frenkel L, Haberer JE, Bangsberg D, Celum C; Partners PrEP Study Team.

Lancet Infect Dis. 2014 Nov;14(11):1055-1064. doi: 10.1016/S1473-3099(14)70937-5. Epub 2014 Oct 7.

12.

Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.

Celum C, Morrow RA, Donnell D, Hong T, Hendrix CW, Thomas KK, Fife KH, Nakku-Joloba E, Mujugira A, Baeten JM; Partners PrEP Study Team.

Ann Intern Med. 2014 Jul 1;161(1):11-9. doi: 10.7326/M13-2471. Erratum in: Ann Intern Med. 2016 Dec 6;165(11):832.

PMID:
24979446
13.

Unreported antiretroviral use by HIV-1-infected participants enrolling in a prospective research study.

Kahle EM, Kashuba A, Baeten JM, Fife KH, Celum C, Mujugira A, Essex M, De Bruyn G, Wald A, Donnell D, John-Stewart G, Delany-Moretlwe S, Mugo NR, Farquhar C, Lingappa JR; Partners in Prevention HSVHIV Transmission Study Team.

J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):e90-4. doi: 10.1097/QAI.0b013e3182a2db02. No abstract available.

14.

Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial.

Mujugira A, Magaret AS, Celum C, Baeten JM, Lingappa JR, Morrow RA, Fife KH, Delany-Moretlwe S, de Bruyn G, Bukusi EA, Karita E, Kapiga S, Corey L, Wald A; Partners in Prevention HSV/HIV Transmission Study Team.

J Infect Dis. 2013 Nov 1;208(9):1366-74. doi: 10.1093/infdis/jit333. Epub 2013 Jul 30.

15.

Plasma viral loads during early HIV-1 infection are similar in subtype C- and non-subtype C-infected African seroconverters.

Campbell MS, Kahle EM, Celum C, Lingappa JR, Kapiga S, Mujugira A, Mugo NR, Fife KH, Mullins JI, Baeten JM; Partners in Prevention HSV/HIV Transmission Study Team.

J Infect Dis. 2013 Apr;207(7):1166-70. doi: 10.1093/infdis/jit015. Epub 2013 Jan 11.

16.

Partner characteristics predicting HIV-1 set point in sexually acquired HIV-1 among African seroconverters.

Lingappa JR, Thomas KK, Hughes JP, Baeten JM, Wald A, Farquhar C, de Bruyn G, Fife KH, Campbell MS, Kapiga S, Mullins JI, Celum C; Partners in Prevention HSV/HIV Transmission Study Team.

AIDS Res Hum Retroviruses. 2013 Jan;29(1):164-71.

17.

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C; Partners PrEP Study Team.

N Engl J Med. 2012 Aug 2;367(5):399-410. doi: 10.1056/NEJMoa1108524. Epub 2012 Jul 11.

18.

Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention.

Mujugira A, Baeten JM, Donnell D, Ndase P, Mugo NR, Barnes L, Campbell JD, Wangisi J, Tappero JW, Bukusi E, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Panteleeff D, Krows M, Shah H, Revall J, Morrison S, Ondrejcek L, Ingram C, Coombs RW, Lingappa JR, Celum C; Partners PrEP Study Team.

PLoS One. 2011;6(10):e25828. doi: 10.1371/journal.pone.0025828. Epub 2011 Oct 5.

19.

Outside sexual partnerships and risk of HIV acquisition for HIV uninfected partners in African HIV serodiscordant partnerships.

Ndase P, Celum C, Thomas K, Donnell D, Fife KH, Bukusi E, Delany-Moretlwe S, Baeten JM; Partners in Prevention HSVHIV Transmission Study Team.

J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):65-71. doi: 10.1097/QAI.0b013e318237b864.

20.

Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies.

Baker DA, Ferris DG, Martens MG, Fife KH, Tyring SK, Edwards L, Nelson A, Ault K, Trofatter KF, Liu T, Levy S, Wu J.

Infect Dis Obstet Gynecol. 2011;2011:806105. doi: 10.1155/2011/806105. Epub 2011 Aug 24.

21.

Performance of the Focus HerpeSelect-2 enzyme immunoassay for the detection of herpes simplex virus type 2 antibodies in seven African countries.

Mujugira A, Morrow RA, Celum C, Lingappa J, Delany-Moretlwe S, Fife KH, Heffron R, De Bruyn G, Homawoo B, Karita E, Mugo N, Vwalika B, Baeten JM; Partners in Prevention HSV/HIV Transmission Study Team.

Sex Transm Infect. 2011 Apr;87(3):238-41. doi: 10.1136/sti.2010.047415. Epub 2011 Feb 9.

22.

Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.

Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N, Sanchez J, Essex M, Makhema J, Kiarie J, Farquhar C, Corey L.

J Infect Dis. 2011 Jan 1;203(1):117-21. doi: 10.1093/infdis/jiq013.

23.

Bariatric surgery outcomes in HIV-infected subjects: a case series.

Selke H, Norris S, Osterholzer D, Fife KH, DeRose B, Gupta SK.

AIDS Patient Care STDS. 2010 Sep;24(9):545-50. doi: 10.1089/apc.2010.0132.

PMID:
20731608
24.

Herpes simplex virus type 2 infection in young adult women: risk factors for infection and frequency of viral shedding.

Fife KH, Williams JA, Thomas AL, Ofner S, Katz BP, Fortenberry JD.

Sex Transm Dis. 2010 Apr;37(4):248-52. doi: 10.1097/OLQ.0b013e3181d4f866.

PMID:
20216477
25.

Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.

Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Magaret AS, Wang RS, Kidoguchi L, Barnes L, Ridzon R, Corey L, Celum C; Partners in Prevention HSV/HIV Transmission Study Team.

Lancet. 2010 Mar 6;375(9717):824-33. doi: 10.1016/S0140-6736(09)62038-9. Epub 2010 Feb 12.

26.

Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.

Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, Mujugira A, Baeten JM, Mullins JI, Hughes JP, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Stevens W, Campbell MS, Thomas KK, Coombs RW, Morrow R, Whittington WL, McElrath MJ, Barnes L, Ridzon R, Corey L; Partners in Prevention HSV/HIV Transmission Study Team.

N Engl J Med. 2010 Feb 4;362(5):427-39. doi: 10.1056/NEJMoa0904849. Epub 2010 Jan 20.

27.

Implementation of routine access to herpes simplex virus type 2 antibody testing in a public health sexually transmitted disease clinic.

Fife KH, Van Der Pol B, Roth AM, Brand J, Arno JN, Madlem J, Juliar BE, Katz BP, Williams JA, Zimet GD, Fortenberry JD.

Sex Transm Dis. 2009 Nov;36(11):724-8. doi: 10.1097/OLQ.0b013e3181bc9a2f.

PMID:
19809384
28.

Once daily valacyclovir for reducing viral shedding in subjects newly diagnosed with genital herpes.

Martens MG, Fife KH, Leone PA, Dix LP, Brennan CA.

Infect Dis Obstet Gynecol. 2009;2009:105376. doi: 10.1155/2009/105376. Epub 2009 Aug 10.

29.

Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy.

Fife KH, Wu JW, Squires KE, Watts DH, Andersen JW, Brown DR.

J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):274-82. doi: 10.1097/QAI.0b013e3181a97be5.

30.

An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.

Fife KH, Warren TJ, Justus SE, Heitman CK; HS2100275 STUDY TEAM.

Sex Transm Dis. 2008 Jul;35(7):668-73. doi: 10.1097/OLQ.0b013e31816d1f42.

PMID:
18461016
31.

The Centers for Disease Control and Prevention revised recommendations for HIV testing: reactions of women attending community health clinics.

Burrage JW, Zimet GD, Cox DS, Cox AD, Mays RM, Fife RS, Fife KH.

J Assoc Nurses AIDS Care. 2008 Jan-Feb;19(1):66-74. doi: 10.1016/j.jana.2007.11.003.

32.
33.

Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions.

Fife KH, Meng TC, Ferris DG, Liu P.

Antimicrob Agents Chemother. 2008 Feb;52(2):477-82. Epub 2007 Nov 26.

34.
35.

A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir.

Fife KH, Almekinder J, Ofner S.

Sex Transm Dis. 2007 May;34(5):297-301.

PMID:
16960547
36.

Down-regulation of MHC class I is a property common to papillomavirus E5 proteins.

Ashrafi GH, Brown DR, Fife KH, Campo MS.

Virus Res. 2006 Sep;120(1-2):208-11. Epub 2006 Jun 15.

PMID:
16780984
37.

Are the antiherpes nucleosides really all the same?

Fife KH.

Sex Transm Dis. 2006 Sep;33(9):534-5. No abstract available.

PMID:
16778740
38.

Herpes virus type 2 infection and genital symptoms in primary care patients.

Fleming DT, Leone P, Esposito D, Heitman CK, Justus S, Chin S, Fife KH.

Sex Transm Dis. 2006 Jul;33(7):416-21.

PMID:
16601657
39.

The psychosocial impact of serological diagnosis of asymptomatic herpes simplex virus type 2 infection.

Rosenthal SL, Zimet GD, Leichliter JS, Stanberry LR, Fife KH, Tu W, Bernstein DI.

Sex Transm Infect. 2006 Apr;82(2):154-7; discussion 157-8.

40.

Incidence and prevalence of herpes simplex virus infections in adolescent women.

Fife KH, Fortenberry JD, Ofner S, Katz BP, Morrow RA, Orr DP.

Sex Transm Dis. 2006 Jul;33(7):441-4.

PMID:
16540882
41.

Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya.

Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, Yiannoutsos CT, Musick B, Einterz R, Fife KH, Tierney WM.

AIDS. 2006 Jan 2;20(1):41-8.

PMID:
16327318
42.

A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects.

de Bruyn G, Vargas-Cortez M, Warren T, Tyring SK, Fife KH, Lalezari J, Brady RC, Shahmanesh M, Kinghorn G, Beutner KR, Patel R, Drehobl MA, Horner P, Kurtz TO, McDermott S, Wald A, Corey L.

Vaccine. 2006 Feb 13;24(7):914-20. Epub 2005 Sep 21.

PMID:
16213066
43.

Predictors of herpes simplex virus type 2 antibody positivity among persons with no history of genital herpes.

Fife KH, Bernstein DI, Tu W, Zimet GD, Brady R, Wu J, Fortenberry JD, Stone KM, Rosenthal SL, Stanberry LR.

Sex Transm Dis. 2004 Nov;31(11):676-81.

PMID:
15502676
44.

Factors predicting the acceptance of herpes simplex virus type 2 antibody testing among adolescents and young adults.

Zimet GD, Rosenthal SL, Fortenberry JD, Brady RC, Tu W, Wu J, Bernstein DI, Stanberry LR, Stone KM, Leichliter JS, Fife KH.

Sex Transm Dis. 2004 Nov;31(11):665-9.

PMID:
15502674
45.

Return for results after herpes simplex virus type 2 screening.

Fortenberry JD, Zimet GD, Brady R, Wu J, Tu W, Stone KM, Rosenthal SL, Bernstein DI, Fife KH.

Sex Transm Dis. 2004 Nov;31(11):655-8.

PMID:
15502672
46.

Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women.

Fife KH, Wheeler CM, Koutsky LA, Barr E, Brown DR, Schiff MA, Kiviat NB, Jansen KU, Barber H, Smith JF, Tadesse A, Giacoletti K, Smith PR, Suhr G, Johnson DA.

Vaccine. 2004 Jul 29;22(21-22):2943-52.

PMID:
15246631
47.

Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine.

Brown DR, Fife KH, Wheeler CM, Koutsky LA, Lupinacci LM, Railkar R, Suhr G, Barr E, Dicello A, Li W, Smith JF, Tadesse A, Jansen KU.

Vaccine. 2004 Jul 29;22(21-22):2936-42.

PMID:
15246630
48.

Poor sensitivity of polymerase chain reaction assays of genital skin swabs and urine to detect HPV 6 and 11 DNA in men.

Fife KH, Coplan PM, Jansen KU, DiCello AC, Brown DR, Rojas C, Su L.

Sex Transm Dis. 2003 Mar;30(3):246-8.

PMID:
12616145
49.

Increased frequency of dosing of imiquimod 5% cream in the treatment of external genital warts in women.

Trofatter KF Jr, Ferenczy A, Fife KH.

Int J Gynaecol Obstet. 2002 Feb;76(2):191-3. No abstract available.

PMID:
11818121
50.

Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer.

Brown DR, Bryan JT, Schroeder JM, Robinson TS, Fife KH, Wheeler CM, Barr E, Smith PR, Chiacchierini L, DiCello A, Jansen KU.

J Infect Dis. 2001 Nov 1;184(9):1183-6. Epub 2001 Sep 27.

PMID:
11598842

Supplemental Content

Support Center